The present invention relates to a pharmaceutical composition containing a pharmaceutically effective amount of amniotic mesenchymal stem cells (AMMs) and a pharmaceutically acceptable support for treating ischemic diseases. The amniotic mesenchymal stem cells according to the present invention express and secrete genes and proteins associated with chemotactic properties, cell migration, and angiogenic properties at a high level as compared with an adipose-derived mesenchymal stem cell. Moreover, the AMMs reduce myocardial infarction; significantly increases the vascular density; promote secretion of multiple paracrine factors; significantly increase left ventricular ejection fraction (LVEF); and thus can be advantageously used for treating ischemic diseases.;COPYRIGHT KIPO 2015
展开▼
